Urinary tract infections (UTIs) refer to the infections that affect any part of the urinary system, including the kidneys, ureters, bladder, and urethra. The infection is usually caused by bacteria that enter through the urethra and bladder. Common symptoms of UTIs include burning sensation during urination and frequent urination in small amounts. Antibiotics are widely used as the primary treatment for UTIs to kill the bacteria causing the infection.
The global Urinary Tract Infection Therapeutic Market is estimated to be valued at US$ 8,665.5 Mn in 2024 and is expected to exhibit a CAGR of 3.0% over the forecast period of 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Rising prevalence of urinary tract infections is a major factor driving the growth of urinary tract infection therapeutic market. According to the National Kidney and Urologic Diseases Information Clearinghouse, UTIs are the most common bacterial infections, with approximately150 million people worldwide suffering from UTI each year. Women are more prone to UTIs as compared to men due to anatomy differences. Increasing geriatric population is also contributing to the rising incidence of UTIs due to weakened immunity. Growing resistance to conventional antibiotics has increased the demand for advanced therapeutics for effective treatment of UTIs. Development of novel drug formulations is expected to bring more treatment options and fuel the market growth over the forecast period.
Segment Analysis
The global urinary tract infection therapeutic market is dominated by the drugs segment. Within the drugs segment, the cephalosporin sub-segment currently holds the largest market share due to high efficacy and wide acceptance among physicians for treating uncomplicated urinary tract infections. However, the demand for quinolones sub-segment is expected to rise during the forecast period owing to expanding therapeutic applications of quinolones in treating both complicated as well as uncomplicated urinary tract infections.
Key Takeaways
The global urinary tract infection therapeutic market is expected to witness high growth over the forecast period of 2023 to 2030. The global Urinary Tract Infection Therapeutic Market is estimated to be valued at US$ 8,665.5 Mn in 2024 and is expected to exhibit a CAGR of 3.0% over the forecast period of 2023 to 2030.
North America currently holds the largest share in the global market due to increasing prevalence of urinary tract infections among populace and higher healthcare expenditure. Europe follows North America closely in terms of market share as majority countries in the region have well-developed healthcare infrastructure. The Asia Pacific region is projected to be the fastest growing market during the forecast period on account rapid economic development and increasing availability of advanced treatment options for urinary tract infections in emerging economies of China and India.
Key players operating in the urinary tract infection therapeutic market are Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC, among others. Pfizer currently dominates the global market due to its diversified product portfolio and strong penetration in developed as well as developing regions. Novartis AG holds the second largest market share owing to its commercial leadership in key global markets.
No comments:
Post a Comment